Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation

Thursday, June 19, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

LOS ANGELES, California, June 18 CanopusBioPharma, Inc. (OTC: CBIA), a biotechnology company developingpharmaceutical products and assay methods for patients suffering frominfectious disease, radiation sickness, cancer and addiction, today announcedthe signing of a licensing agreement with the Wisconsin Alumni ResearchFoundation (WARF), an organization serving the University ofWisconsin-Madison scientific community by patenting the discoveries ofUW-Madison researchers and licensing these technologies to leading companiesin Wisconsin, the United States and worldwide. The agreement providescomprehensive licensing rights and patent protection relating to Canopus'Phase II oncology drug candidate, CB1400.

"Securing the rights to the WARF patents strengthens Canopus BioPharma'sintellectual property position for future licensing opportunities of CB1400,one of our most exciting products," said Patrick Prendergast, Chairman andChief Executive Officer of Canopus BioPharma. "In the near future, we expectto announce important results from our studies using CB1400, which willfurther validate the potential significance of our drug for oncology andrelated indications."

Canopus BioPharma expects to develop CB1400 as a method for preventingand reducing mucositis (lesions in the gastrointestinal and oral mucosacaused by chemo- and/or radiotherapy). The domestic market alone for apreventative anti-mucositis agent is estimated to be over $1 billion perannum. The compound underlying CB1400 had been previously developed andpatented by a major pharmaceutical company as an anti-parasitic agent.Canopus discovered that this approved drug was highly effective for analternative indication, specifically for use in preventing mucositis. CanopusBioPharma's market opportunity with CB1400 includes various applicationsassociated with cancer therapy and cancer treatment side effects.

CB1400, a former anti-schistosomal drug, is currently in phase IIclinical development by Canopus as an anti-mucositis preventative agent inpatients receiving radio- and/or chemotherapy treatment. CB1400 alone and incombination with both cisplatin and cetuximab (Erbitux), has also been shownto inhibit tumor growth in two mice models of lung cancer, thus demonstratingthe broad capabilities of this compound in the treatment of cancer.

About the Wisconsin Alumni Research Foundation:

The Wisconsin Alumni Research Foundation (WARF) supports research at theUniversity of Wisconsin-Madison by protecting the intellectual property ofUniversity faculty, staff and students, and licensing inventions resultingfrom their work. Through these efforts, university ideas benefit the publicby bringing resources back to the university to continue the cycle ofinvestment, research and invention. WARF ( was established in1925 as the first university-based technology transfer office in the world.

About Canopus BioPharma, Inc.:

Canopus BioPharma, Inc. (OTC: CBIA) is dedicated to providing the safest,most cost effective and efficacious pharmaceutical products and assay methodsin the areas of infectious disease, radiation protection, cancer, andaddiction. With innovative science, proven research and developmentleadership, and superior products and compounds, Canopus BioPharma has, since2001, been committed to becoming a market trend setter in a new era ofhealthcare. In addition, the Company is a world leader in the development ofnovel camelid antibody products to provide unique avenues of progress andimprovement in assay methods and monitoring capabilities for physicians,patients and researchers, initially for food chain protection applications.Canopus maintains staff in Australia, South Africa, Ireland, Panama and theUSA. Additional information on the Company is available at

SOURCE Canopus BioPharma, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store